Skip to main content
. Author manuscript; available in PMC: 2014 Jul 8.
Published in final edited form as: Clin Cancer Res. 2013 Aug 21;19(19):5505–5512. doi: 10.1158/1078-0432.CCR-12-3327

Table 2.

Characteristics of patients with clinical benefit

Pts with clinical
benefit on
bicalutamide		 AR% ER% PgR% HER2 Site of
testing		 Site of
metastases		 Prior
therapy
LABC/MBC		 DOR on
prior therapy,
wks		 DOR on
bicalutamide,
wks
#1 10–20 1 0 Neg P LN 0 NA 231+
#2 >80 3 0 Neg Met GI 0 NA 54
#3 >80 0 0 −/+ P Breast LN 1 NR 25
#4 >90 0 0 Neg P LN Bone 1 158 35
#5 >50 0 0 Neg P LN Bone 1 15 43+

Abbreviations: DOR, duration of response; GI, gastrointestinal; LABC, locally advanced breast cancer; LN, lymph node; Met, metastasis; NA, not applicable; NR, no response; P, primary tumor.